长春高新：关于子公司GS3-007a干混悬剂境内生产药品注册临床试验申请获得受理的公告

Core Points - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a dry suspension for domestic production [1] Group 1 - The acceptance of the clinical trial application indicates progress in the development of GS3-007a, which may enhance the company's product pipeline [1] - This regulatory approval is a significant step for Changchun Jinsai Pharmaceutical in advancing its research and development efforts [1]